About Etibo 250 mg
Etibo 250 mg by Cipla is a hot-selling, exclusive oncology solution formulated with radiant expertise. Each light yellow, film coated, odorless tablet contains 250 mg of top-notch Erlotinib Hydrochloride, designed for oral administration. This inestimable prescription medicine, under ATC Code L01EB02, targets non-small cell lung cancer and pancreatic cancer with proven efficacy. Packaged in a convenient blister strip and registered as per local certifications, Etibo 250 mg offers limited time access for authorized healthcare providers. For safety, it requires an oncologist's prescription and must be stored in a cool, dry place. Proudly originating from India, Etibo 250 mg represents unparalleled quality from a trusted distributor, supplier, and trader.
Etibo 250 mg: Targeted Therapy Excellence
Etibo 250 mg is optimally used for oral anticancer therapy, primarily treating non-small cell lung cancer and pancreatic cancer. Its targeted mechanism offers a radiant, precise approach, maximizing treatment efficacy while limiting unnecessary side effects. As a top-notch prescription solution from Cipla, Etibo 250 mg meets stringent global regulatory standards, ensuring plant-origin performance and competitive advantages in potency and reliability. Its versatile application aligns with inestimable clinical needs across oncology practices.
Etibo 250 mg: Payment, Export Markets, and Swift Delivery
With stock ready for immediate shipment, Etibo 250 mg is available at a competitive sale price that reflects its superior value. Proposal amounts are tailored based on volume and destination market requirements. Our main export markets include Asia, Africa, Latin America, and the Middle East. Delivery time is swift and efficient, supporting urgent procurement needs for authorized medical distributors, suppliers, and traders globally.
FAQ's of Etibo 250 mg:
Q: How should Etibo 250 mg be administered for optimal results?
A: Etibo 250 mg should be administered orally, strictly following the oncologist's prescription and dosage guidelines. Ensure the tablet is swallowed whole with water and not crushed or chewed.
Q: What are the primary indications for prescribing Etibo 250 mg?
A: Etibo 250 mg is primarily indicated for the treatment of non-small cell lung cancer and pancreatic cancer as part of targeted anticancer therapy.
Q: When is Etibo 250 mg typically recommended by healthcare professionals?
A: Oncologists recommend Etibo 250 mg when targeted therapy with Erlotinib is deemed appropriate based on the cancer type and patient's medical profile. It is prescribed only after thorough clinical assessment.
Q: Where can Etibo 250 mg be legally purchased or sourced?
A: Etibo 250 mg is available only through registered pharmacies and authorized oncology distributors or traders. It can be sold by retail strictly on the prescription of a qualified oncologist.
Q: What benefits does Etibo 250 mg offer over traditional chemotherapy options?
A: Etibo 250 mg provides a targeted approach, minimizing the impact on healthy cells and potentially reducing the severity of side effects compared to traditional chemotherapy regimens, while delivering inestimable efficacy in specific cancer types.
Q: What storage conditions are required for maintaining Etibo 250 mg's quality?
A: Etibo 250 mg must be kept in a cool, dry place, away from moisture and direct sunlight, to preserve its effectiveness throughout its 24-month shelf life.